Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Egetis Gets Conditional FDA Name Acceptance

    Picture of Egetis Therapeutics AB (publ) logoEgetis Therapeutics AB (publ)
    08/04/2026 12:21
    April 8 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

RECEIVES CONDITIONAL FDA ACCEPTANCE OF PROPRIETARY NAME EMCITATE

FINAL APPROVAL OF EMCITATE NAME RESERVED UNTIL NDA APPROVAL

APPLICATION GRANTED PRIORITY REVIEW WITH PDUFA DATE OF SEPTEMBER 28, 2026

Source text: ID:nMFN1Xh7mf

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Egetis Therapeutics AB (publ)

    See all news